Editing Imatinib (section)

===Other===
The FDA has approved imatinib for use in adults with relapsed or refractory Philadelphia chromosome-positive [[acute lymphoblastic leukemia]] (Ph+ ALL), [[myelodysplastic]]/[[myeloproliferative]] diseases associated with [[PDGFR|platelet-derived growth factor receptor]] gene rearrangements, aggressive systemic [[mastocytosis]] without or an unknown D816V c-KIT mutation, [[hypereosinophilic syndrome]] and/or [[chronic eosinophilic leukemia]] who have the [[FIP1L1#FIP1L1-PDGFRA|FIP1L1-PDGFRα]] fusion kinase (CHIC2 allele deletion) or FIP1L1-PDGFRα fusion kinase negative or unknown, unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.<ref name="FDA" /> On 25 January 2013, Gleevec was approved for use in children with Ph+ ALL.<ref>{{cite web|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm|title=FDA approves Gleevec for children with acute lymphoblastic leukemia|date=25 January 2013|work=FDA News Release|publisher=US Food and Drug Administration|access-date=3 April 2013|url-status=dead|archive-url=https://web.archive.org/web/20130310094645/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336868.htm|archive-date=10 March 2013}}</ref>

For treatment of progressive [[Neurofibroma#Plexiform neurofibroma|plexiform neurofibromas]] associated with [[neurofibromatosis type I]], early research has shown potential for using the c-KIT tyrosine kinase blocking properties of imatinib.<ref name="pmid18984156">{{cite journal |vauthors=Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, Li X, Yang X, Knowles S, Horn W, Li Y, Zhang S, Yang Y, Vakili ST, Yu M, Burns D, Robertson K, Hutchins G, Parada LF, Clapp DW | title = Nf1-dependent tumors require a microenvironment containing Nf1+/--and c-kit-dependent bone marrow | journal = Cell | volume = 135 | issue = 3 | pages = 437–48 |date=October 2008 | pmid = 18984156 | pmc = 2788814 | doi = 10.1016/j.cell.2008.08.041 |doi-access=free }}
*{{lay source |template = cite press release|url=https://www.sciencedaily.com/releases/2008/10/081030123837.htm|title = Gleevec Holds Potential As First Drug To Successfully Treat Neurofibromatosis, Scientists Report|date = 31 October 2008 |website = ScienceDaily }}</ref><ref>{{cite web|url=http://www.nfcure.org/newnf1trial/gleevecnf1trial.html|title=Gleevec NF1 Trial|publisher=Nfcure.org|access-date=3 April 2013|url-status=dead|archive-url=https://web.archive.org/web/20120420015449/http://nfcure.org/newnf1trial/gleevecnf1trial.html|archive-date=20 April 2012}}</ref><ref>{{cite web |url=http://www.gistsupport.org/about-gist/gist-in-neurofibromatosis-1.php |title=GIST in Neurofibromatosis 1 |publisher=Gistsupport.org |date=14 May 2010 |access-date=3 April 2013 |url-status=dead |archive-url=https://web.archive.org/web/20130329203014/http://www.gistsupport.org/about-gist/gist-in-neurofibromatosis-1.php |archive-date=29 March 2013 }}</ref><ref>{{cite web|url=http://clinicaltrials.gov/ct2/show/NCT01140360|title="Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas (0908-09)" (Suspended)|publisher=Clinicaltrials.gov|access-date=3 April 2013|url-status=live|archive-url=https://web.archive.org/web/20130703202412/http://www.clinicaltrials.gov/ct2/show/NCT01140360|archive-date=3 July 2013}}</ref> There have been several [[Phase 2 clinical testing|phase 2]] trials of imatinib for [[aggressive fibromatosis]].<ref>{{cite journal | vauthors = Kasper B, Gruenwald V, Reichardt P, Bauer S, Rauch G, Limprecht R, Sommer M, Dimitrakopoulou-Strauss A, Pilz L, Haller F, Hohenberger P  | title = Imatinib induces sustained progression arrest in RECIST progressive desmoid tumours: Final results of a phase II study of the German Interdisciplinary Sarcoma Group (GISG) | journal = European Journal of Cancer | volume = 76 | pages = 60–67 | date = May 2017 | pmid = 28282612 | doi = 10.1016/j.ejca.2017.02.001 | s2cid = 3630670 }}</ref><ref>{{cite journal | vauthors = Mangla A, Agarwal N, Schwartz G | title = Desmoid Tumors: Current Perspective and Treatment | journal = Current Treatment Options in Oncology | volume = 25 | issue = 2 | pages = 161–175 | date = February 2024 | pmid = 38270798 | pmc = 10873447 | doi = 10.1007/s11864-024-01177-5 | doi-access = free }}</ref>